Provention Bio to Present at Upcoming Virtual Investor Conferences

Rhea-AI Summary

Provention Bio, Inc. (Nasdaq: PRVB), a biopharmaceutical company, announced its participation in three virtual investor conferences in September 2020. The presentations include the H.C. Wainwright Global Investment Conference on September 14 at 1:00 PM E.T., the Cantor Fitzgerald Healthcare Conference on September 16 at 11:20 AM E.T., and the Oppenheimer Life Sciences Summit on September 22 at 11:40 AM E.T. Each presentation will be webcast live and archived for 90 days. Provention focuses on preventing immune-mediated diseases, notably type 1 diabetes, with its candidate drug teplizumab.

RED BANK, N.J., Sept. 8, 2020 /PRNewswire/ -- Provention Bio, Inc. (Nasdaq: PRVB), a biopharmaceutical company dedicated to intercepting and preventing immune-mediated disease, today announced that management will present at three upcoming virtual investor conferences in September:

• The H.C. Wainwright 22^nd Annual Global Investment Conference on Monday, September 14, 2020, at 1:00 pm E.T. 
• The Cantor Fitzgerald Global Healthcare Conference on Wednesday, September 16, 2020, at 11:20 am E.T. 
• The Oppenheimer Fall Healthcare Life Sciences & MedTech Summit on Tuesday, September 22, 2020, at 11:40 am E.T.

Each presentation will be webcast live and can be accessed by visiting the Events and Webcasts section of the Company's website: http://investors.proventionbio.com/events. Each webcast will be archived on the Company's website for 90 days following the presentation.

About Provention Bio, Inc.

Provention Bio, Inc. (Nasdaq: PRVB) is a biopharmaceutical company leveraging a transformational drug development strategy focused on the prevention or interception of immune-mediated disease. Provention's mission is to source, transform and develop therapeutic candidates targeting the high morbidity, mortality and escalating costs of autoimmune diseases. Provention's diversified portfolio includes teplizumab, a clinical-stage candidate that has been shown in a clinical study to delay the onset of insulin-dependent type 1 diabetes (T1D) in at-risk patients during the presymptomatic phase of the disease as compared to placebo. The Company's portfolio includes additional clinical product development candidates that have demonstrated in pre-clinical or clinical studies proof-of-mechanism and/or proof-of-concept in other autoimmune diseases, including celiac disease and lupus.

Investor Contact:
Sam Martin, Argot Partners
sam@argotpartners.com   
212-600-1902

Media:
Lori Rosen, LDR Communications
lori@ldrcommunications.com
917-553-6808

View original content to download multimedia:http://www.prnewswire.com/news-releases/provention-bio-to-present-at-upcoming-virtual-investor-conferences-301124367.html

SOURCE Provention Bio, Inc.

FAQ

What is Provention Bio planning for September 2020?

Provention Bio will present at three virtual investor conferences in September 2020: the H.C. Wainwright Conference, the Cantor Fitzgerald Conference, and the Oppenheimer Summit.

When will Provention Bio present at the H.C. Wainwright Conference?

Provention Bio will present at the H.C. Wainwright 22nd Annual Global Investment Conference on September 14, 2020, at 1:00 PM E.T.

What are the dates of Provention Bio's upcoming investor conferences?

Provention Bio's conferences are on September 14, 16, and 22, 2020.

How can I watch the presentations from Provention Bio?

The presentations will be webcast live, accessible via the Events and Webcasts section on Provention Bio's website.

What is teplizumab, related to Provention Bio?

Teplizumab is a clinical-stage candidate drug from Provention Bio designed to delay the onset of insulin-dependent type 1 diabetes in at-risk patients.